Literature DB >> 28797023

Assessing Antiretroviral Use During Gaps in HIV Primary Care Using Multisite Medicaid Claims and Clinical Data.

Anne K Monroe1, John A Fleishman, Cindy C Voss, Jeanne C Keruly, Ank E Nijhawan, Allison L Agwu, Judith A Aberg, Richard M Rutstein, Richard D Moore, Kelly A Gebo.   

Abstract

BACKGROUND: Some individuals who appear poorly retained by clinic visit-based retention measures are using antiretroviral therapy (ART) and maintaining viral suppression. We examined whether individuals with a gap in HIV primary care (≥180 days between HIV outpatient clinic visits) obtained ART during that gap after 180 days.
SETTING: HIV Research Network data from 5 sites and Medicaid Analytic Extract eligibility and pharmacy data were combined.
METHODS: Factors associated with having both an HIV primary care gap and a new (ie, nonrefill) ART prescription during a gap were evaluated with multinomial logistic regression.
RESULTS: Of 6892 HIV Research Network patients, 6196 (90%) were linked to Medicaid data, and 4275 had any Medicaid ART prescription. Over half (54%) had occasional gaps in HIV primary care. Women, older people, and those with suppressed viral load were less likely to have a gap. Among those with occasional gaps (n = 2282), 51% received a new ART prescription in a gap. Viral load suppression before gap was associated with receiving a new ART prescription in a gap (odds ratio = 1.91, 95% confidence interval: 1.57 to 2.32), as was number of days in a gap (odds ratio = 1.04, 95% confidence interval: 1.02 to 1.05), and the proportion of months in the gap enrolled in Medicaid.
CONCLUSIONS: Medicaid-insured individuals commonly receive ART during gaps in HIV primary care, but almost half do not. Retention measures based on visit frequency data that do not incorporate receipt of ART and/or viral suppression may misclassify individuals who remain suppressed on ART as not retained.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28797023      PMCID: PMC5588917          DOI: 10.1097/QAI.0000000000001469

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  21 in total

1.  Retention in care is more strongly associated with viral suppression in HIV-infected patients with lower versus higher CD4 counts.

Authors:  Baligh R Yehia; Benjamin French; John A Fleishman; Joshua P Metlay; Stephen A Berry; P Todd Korthuis; Allison L Agwu; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

2.  Retention in care of adults and adolescents living with HIV in 13 U.S. areas.

Authors:  H Irene Hall; Kristen Mahle Gray; Tian Tang; Jianmin Li; Luke Shouse; Jonathan Mermin
Journal:  J Acquir Immune Defic Syndr       Date:  2012-05-01       Impact factor: 3.731

3.  Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Authors:  R S Hogg; B Yip; K J Chan; E Wood; K J Craib; M V O'Shaughnessy; J S Montaner
Journal:  JAMA       Date:  2001-11-28       Impact factor: 56.272

Review 4.  The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection.

Authors:  Edward M Gardner; Margaret P McLees; John F Steiner; Carlos Del Rio; William J Burman
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

5.  The association of clinical follow-up intervals in HIV-infected persons with viral suppression on subsequent viral suppression.

Authors:  April Buscher; Michael Mugavero; Andrew O Westfall; Jeanne Keruly; Richard Moore; Mari-Lynn Drainoni; Meg Sullivan; Tracey E Wilson; Allan Rodriguez; Lisa Metsch; Lytt Gardner; Gary Marks; Faye Malitz; Thomas P Giordano
Journal:  AIDS Patient Care STDS       Date:  2013-07-26       Impact factor: 5.078

6.  Vital signs: HIV prevention through care and treatment--United States.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-12-02       Impact factor: 17.586

Review 7.  The state of engagement in HIV care in the United States: from cascade to continuum to control.

Authors:  Michael J Mugavero; K Rivet Amico; Tim Horn; Melanie A Thompson
Journal:  Clin Infect Dis       Date:  2013-06-23       Impact factor: 9.079

8.  Measuring retention in HIV care: the elusive gold standard.

Authors:  Michael J Mugavero; Andrew O Westfall; Anne Zinski; Jessica Davila; Mari-Lynn Drainoni; Lytt I Gardner; Jeanne C Keruly; Faye Malitz; Gary Marks; Lisa Metsch; Tracey E Wilson; Thomas P Giordano
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-15       Impact factor: 3.731

9.  Retention among North American HIV-infected persons in clinical care, 2000-2008.

Authors:  Peter Rebeiro; Keri N Althoff; Kate Buchacz; John Gill; Michael Horberg; Hartmut Krentz; Richard Moore; Timothy R Sterling; John T Brooks; Kelly A Gebo; Robert Hogg; Marina Klein; Jeffrey Martin; Michael Mugavero; Sean Rourke; Michael J Silverberg; Jennifer Thorne; Stephen J Gange
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

10.  Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada.

Authors:  Peter F Rebeiro; Alison G Abraham; Michael A Horberg; Keri N Althoff; Baligh R Yehia; Kate Buchacz; Bryan M Lau; Timothy R Sterling; Stephen J Gange
Journal:  AIDS Patient Care STDS       Date:  2017-02-27       Impact factor: 5.078

View more
  2 in total

1.  Annual and durable HIV retention in care and viral suppression among patients of Peter Ho Clinic, 2013-2017.

Authors:  Debbie Y Mohammed; Lisa Marie Koumoulos; Eugene Martin; Jihad Slim
Journal:  PLoS One       Date:  2020-12-29       Impact factor: 3.240

2.  Despite early Medicaid expansion, decreased durable virologic suppression among publicly insured people with HIV in Washington, DC: a retrospective analysis.

Authors:  Deborah Goldstein; W David Hardy; Anne Monroe; Qingjiang Hou; Rachel Hart; Arpi Terzian
Journal:  BMC Public Health       Date:  2020-04-16       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.